Clinical trialPhase 4Withdrawn
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
- Outcome
- Stopped earlySuspended due to Primary Investigator's decision (Other)
- Phase
- Phase 4
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- 25 June 2019
- Planned end
- 1 June 2020
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of HLA-DR,; Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 26 June 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab for the treatment of surgically resectable pancreatic cancer. The primary purpose of this study is to determine the change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab.